Novartis Q2 2026 Earnings
Net Sales $14.41B (est $13.94B) - Core EPS $2.41 (est $2.16) - Promacta/Revolade Sales $179M (est $202.1M) - Tasigna Sales $142M (est $147.2M) - Kisqali Sales $1.70B (est $1.68B) - Pluvicto Sales $651M (est $671.7M) - Entresto Sales $1.18B (est $1.29B) - Cosentyx Sales $1.82B (est $1.14B) - FY 2026 Guidance Reaffirmed
Story updates
05:13:49 AM UTC
SquawkNews
Novartis Q2 2026 Earnings
Net Sales $14.41B (est $13.94B) - Core EPS $2.41 (est $2.16) - Promacta/Revolade Sales $179M (est $202.1M) - Tasigna Sales $142M (est $147.2M) - Kisqali Sales $1.70B (est $1.68B) - Pluvicto Sales $651M (est $671.7M) - Entresto Sales $1.18B (est $1.29B) - Cosentyx Sales $1.82B (est $1.14B) - FY 2026 Guidance Reaffirmed